Narrative
In March 2020, the spin out company Complement Therapeutics was formed based on our research into the ways the Complement System (also known as the complement cascade) which is part of the immune system) works, and how it is dysregulated in age-related macular degeneration. Complement Therapeutics aims to develop innovative and effective therapies to address unmet needs in complement mediated diseases such as dry age-related macular degeneration AMD which affects millions and for which there is currently no effective treatment.Its lead product is CTx001, an innovative gene therapy for the treatment of Geographic Atrophy (GA) secondary to dry AMD.
In February 2022, the company secured EUR 5 million in seed financing.
In November 2022 MHRA MHRA granted Complement Therapeutics an Innovation Passport under the new accelerated Innovative Licensing and Access Pathway (ILAP) for CTx001 to accelerate Gene Therapy for GA (ILAP is designed to optimise the development and expedite the evaluation of innovative medicines for patients with high unmet need).
In April 2023 the company secured a further EUR 72 million financing to continue the development of CTx001 and grow it's lab space in Stevenage.
Impact date | 2019 |
---|---|
Category of impact | Health and wellbeing, Economic |
Impact level | Engagement |
Research Beacons, Institutes and Platforms
- Manchester Institute for Collaborative Research on Ageing
Documents & Links
Related content
-
Research output
-
Beyond factor H: The impact of genetic-risk variants for age-related macular degeneration on circulating factor-H-like 1 and factor-H-related protein concentrations
Research output: Contribution to journal › Article › peer-review
-
Mast cell infiltration of the choroid and protease release are early events in age-related macular degeneration associated with genetic risk at both chromosome 1q32 and 10q26
Research output: Contribution to journal › Article › peer-review
-
Increased circulating levels of Factor H-Related Protein 4 are strongly associated with age-related macular degeneration
Research output: Contribution to journal › Article › peer-review